Apogee hits "pipeline-in-a-product" milestone with positive asthma data

Apogee Therapeutics (NASDAQ:APGE) shares are trending today after the company reported positive interim Phase 1b results for zumilokibart (APG777), its half-life extended anti-IL-13 antibody.

The data marks a successful expansion beyond atopic dermatitis into the respiratory market, showcasing the drug's potential as a "best-in-class" therapy for mild-to-moderate asthma.

In the 19-patient study, a single 720 mg dose of zumilokibart delivered a 60% mean reduction in fractional exhaled nitric oxide (FeNO), a critical biomarker for Type 2 inflammation.

This absolute reduction of 45 ppb was remarkably durable, with suppression maintained through 16 weeks for all participants, and through 32 weeks for those with available follow-up.

These findings strongly support the potential for a quarterly (every 3 months) or even semi-annual (every 6 months) dosing schedule, which would represent a major competitive advantage over currently available biologics that require more frequent injections.

Meanwhile, zumilokibart demonstrated a favorable safety profile with no serious adverse events or Grade 3+ toxicities.

Notably, the study reported zero cases of conjunctivitis (a common side effect of IL-13 inhibitors) and no injection-site reactions.

With a massive cash position of $913 million, Apogee is well-funded through 2028 as it prepares for a flurry of 2026 catalysts, including the initiation of a Phase 3 program for atopic dermatitis in the second half of the year.